Last reviewed · How we verify
HM781-36B tablets
At a glance
| Generic name | HM781-36B tablets |
|---|---|
| Also known as | HM781-36B |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PHASE3)
- Study of Poziotinib in Japanese Patients With NSCLC (PHASE1, PHASE2)
- Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation (PHASE2)
- A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies (PHASE2)
- Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer (PHASE2)
- A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants (PHASE1)
- A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer (PHASE1)
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HM781-36B tablets CI brief — competitive landscape report
- HM781-36B tablets updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI